Therefore, it may be envisaged that targeting XPO1 by SINE or PAK4 by KPT-9274 may serve to reduce the dose and frequency of lenvatinib regimen required to achieve therapeutic effects in anaplastic thyroid cancer. Here, XPO1 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.